Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12...1314151617181920212223...15251526»
  • ||||||||||  GH35 / Genhouse Bio
    Enrollment closed, Enrollment change, Metastases:  Dose Finding Study of GH35 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  May 23, 2024   
    P1,  N=18, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=38 --> 18
  • ||||||||||  Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in Sarcoma: Current Data and Promising Strategies. (Pubmed Central) -  May 23, 2024   
    Thus, although rare, breast cancer radiotherapy is associated with an increased risk of thoracic soft tissue sarcoma in the Japanese population. Traditionally sarcomas have been considered immunologically quiet tumours, with low tumour mutational burden (TMB) and an immunosuppressive tumour microenvironment (TME), consisting of decreased T-cell infiltration and elevated levels of H1F1?, macrophages and neutrophils.1,2 However, research has shown that a subset of sarcomas are immunologically 'hot' with either high TMB, PDL-1 expression, CD8+ T cells or presence of tertiary lymphoid structures (TLS) demonstrating sensitivity to immunotherapy.3,4 Here, we review the current evidence for immunotherapy use in bone sarcomas (BS) and soft tissue sarcomas (STS), with immune checkpoint inhibitors (ICI) and adoptive cellular therapies including engineered T-cell therapies, chimeric antigen receptor (CAR) T-cell therapies, tumour infiltrating lymphocytes (TILs) and cancer vaccines and biomarkers of response.
  • ||||||||||  Journal:  Napsin A Immunoreactivity in "Hobnail" Epithelium in Benign Endometrial and Endocervical Polyps. (Pubmed Central) -  May 23, 2024   
    In addition, in 2 of 3 uterine adenosarcomas with focal hobnail change the epithelium was Napsin A positive. Pathologists should be aware that Napsin A may be expressed in benign/reactive hobnail epithelium in endometrial and endocervical polyps and should not consider positivity with this marker as a diagnostic of clear cell carcinoma.
  • ||||||||||  erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
    Journal:  Pacidusin B isolated from Phyllanthus acidus triggers ferroptotic cell death in HT1080 cells. (Pubmed Central) -  May 23, 2024   
    Furthermore, the molecular docking study showed that pacidusin B docked in the same pocket in xCT as the ferroptosis inducer erastin. These results revealed that pacidusin B exerts anticancer effects via inducing ER-mediated ferroptotic cell death.
  • ||||||||||  Journal:  Malignant Transformation in a Chondroblastoma-Does it Exist? (Pubmed Central) -  May 23, 2024   
    The patient defaulted to further treatment and unfortunately died 8 months, post-diagnosis. The conceptual evolution of a malignant chondroblastoma with H3K36M immunostaining in the few reported tumors is described herewith.
  • ||||||||||  Journal, EGFR exon 20, HER2 exon 20:  A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome. (Pubmed Central) -  May 23, 2024   
    Young patients affected by oncogene-addicted non-small cell lung cancer and with a positive familial cancer history should be referred for an accurate genetic counselling to look for Li Fraumeni syndrome. The underlying molecular connection between TP53 and HER family receptor tyrosine kinases remains unclear, but an extensive molecular characterization of tumors from patients with Li Fraumeni syndrome should always be performed, to offer patients a personalized therapeutic approach.
  • ||||||||||  Tavegil (clemastine) / GSK
    Journal:  Clemastine and hyperthermia enhance sensitization of osteosarcoma cells for apoptosis. (Pubmed Central) -  May 23, 2024   
    These results indicate that clemastine and hyperthermia sensitize OS cell lines by inducing increased autophagic cell death. Collectively, our data suggest that hyperthermia along with antihistamine therapy may provide an improved approach for the treatment of OS.
  • ||||||||||  Journal:  Pediatric orbital lesions: neoplastic extraocular soft-tissue lesions. (Pubmed Central) -  May 22, 2024   
    In this paper, the authors present a multimodality approach to the imaging work-up of these lesions and highlight the use of ocular ultrasound as a first imaging modality where appropriate. We will discuss vascular neoplasms (congenital hemangioma, infantile hemangioma), optic nerve lesions (meningioma, optic nerve glioma), and other neoplastic lesions (plexiform neurofibroma, teratoma, chloroma, rhabdomyosarcoma, infantile fibrosarcoma, schwannoma).
  • ||||||||||  Journal:  Niclosamide: A career builder. (Pubmed Central) -  May 22, 2024   
    To enable such endeavors, I give many proposed ideas throughout the document, that have been stimulated and inspired by gaps in the literature, urgent needs in disease, and new studies arising from our own work. The hope is that, by reading through this document and studying the suggested topics and references, the drug delivery and development community will continue our lineage and benefit from our legacy to achieve niclosamide's potential as an effective contributor to the treatment and control of many diseases and conditions.
  • ||||||||||  Journal:  Clear cell sarcoma: Imaging findings of a newly described tumor entity (Pubmed Central) -  May 22, 2024   
    The hope is that, by reading through this document and studying the suggested topics and references, the drug delivery and development community will continue our lineage and benefit from our legacy to achieve niclosamide's potential as an effective contributor to the treatment and control of many diseases and conditions. No abstract available
  • ||||||||||  Journal:  Fructose-mineralized black phosphorus for syncretic bone regeneration and tumor suppression. (Pubmed Central) -  May 22, 2024   
    In vivo experiments affirmed the anti-tumor capability, inhibition of tumor recurrence and bone repair promotion of CaBPs-Na2FDP@CaCl2. This study not only broadens the application of BPs in bone tumor therapy but also provides a versatile surface functionalization strategy for nanotherapeutic agents.
  • ||||||||||  Biomarker, Review, Journal:  Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances. (Pubmed Central) -  May 22, 2024   
    Although a histopathologically diverse subset of tumors, papillary RCC is canonically associated with amplification of the MET protooncogene; recently completed and ongoing trials have investigated MET-directed therapies for this patient population. Finally, we discuss the unique biology of RCC with sarcomatoid dedifferentiation and the recent clinical findings detailing its paradoxical sensitivity to ICIs.
  • ||||||||||  Journal:  Mapping the Single-cell Differentiation Landscape of Osteosarcoma. (Pubmed Central) -  May 22, 2024   
    Finally, we discuss the unique biology of RCC with sarcomatoid dedifferentiation and the recent clinical findings detailing its paradoxical sensitivity to ICIs. Our study quantifies OS differentiation and lineage, a prerequisite to better understanding lineage-specific differentiation bottlenecks that might someday be targeted therapeutically.
  • ||||||||||  Biomarker, Journal, IO biomarker:  Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma. (Pubmed Central) -  May 22, 2024   
    Notably, dedifferentiated ChRCC share gene enrichment and pathway activation features with other sarcomatoid RCC, suggesting convergent evolutionary trajectories. This study expands our understanding of aggressive ChRCC, provides insight into molecular mechanisms of tumor progression, and informs pathologic classification and diagnostics.
  • ||||||||||  erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
    Journal:  KRAS depletion suppresses ferroptosis and affects Hippo pathway in cataract. (Pubmed Central) -  May 22, 2024   
    Erastin was applied for inducing ferroptosis in hydrogen peroxide (H2O2)-treated SRA01/04 cells, and validated by detecting content of intracellular iron, glutathione (GSH), malondialdehyde (MDA)...Additionally, KRAS deficiency was involved in the Hippo signalling pathway activation. Downregulation of KRAS might restrain ferroptosis and affect Hippo pathway in cataract.
  • ||||||||||  Journal, Biopsy:  MRI Differential Diagnosis and Guidance for Puncture Biopsy of Musculoskeletal Dedifferentiated Liposarcoma and Well Differentiated Liposarcoma. (Pubmed Central) -  May 22, 2024   
    DD has a greater proportion of non-fatty components, with more complex and inhomogeneous MRI signals, and typically shows significant enhancement, with usually indistinct margins of the tumor, in which the inhomogeneous manifestations are associated with the histological components. The possibility of DD should be considered in fatty tumors with non-fatty areas > 25%, for which puncture biopsy is necessary, while simultaneous puncture of low, moderate, high-signal areas within the non-fatty area could improve the accuracy of preoperative puncture pathology.
  • ||||||||||  Journal:  ATRX guards against aberrant differentiation in mesenchymal progenitor cells. (Pubmed Central) -  May 22, 2024   
    Finally, we demonstrated that loss of ATRX in a mesenchymal malignancy, undifferentiated pleomorphic sarcoma, results in similar epigenetic disruption and de-repression of transposable elements. Together, our results reveal a role for ATRX in maintaining epigenetic states and transcriptional repression in mesenchymal progenitors and tumor cells and in
  • ||||||||||  Journal:  Unveiling the role of KSHV-infected human mesenchymal stem cells in Kaposi's sarcoma initiation. (Pubmed Central) -  May 22, 2024   
    Under proangiogenic environmental conditions, KSHV can reprogram hMSCs to exhibit gene expression profiles more similar to KS tumors, activating cell cycle progression, cytokine signaling pathways, endothelial differentiation, and upregulating KSHV oncogenes indicating the involvement of KSHV infection in inducing the mesenchymal-to-endothelial (MEndT) transition of hMSCs. This finding underscores the significance of this condition in facilitating KSHV-induced proliferation and reprogramming of hMSCs towards MEndT and closer to KS gene expression profiles, providing further evidence of these cell subpopulations as precursors of KS cells that thrive in a proangiogenic environment.
  • ||||||||||  ENHANCED SUPPORTIVE CARE IN THE LONDON SARCOMA SERVICE (E-Poster #3, Hall Lille, Floor 1) -  May 22, 2024 - Abstract #MASCCAFSOSISOO2024MASCC_AFSOS_ISOO_682;    
    Conclusions ESC provides specialist symptom control for patients with incurable disease. This model of care reduces symptom burden and connects sarcoma patients with community support.
  • ||||||||||  Supportive care needs in male cancer patients (E-Poster #3, Hall Lille, Floor 1) -  May 22, 2024 - Abstract #MASCCAFSOSISOO2024MASCC_AFSOS_ISOO_663;    
    The final analysis will be provided during the meeting. Conclusions Our results showed that male cancer patients expressed fewer supportive care needs, suggesting that this population should be more thoroughly screened for supportive care.